No products in the cart.
Temozolomide Capsules
$1.00
Temozolomide 100mg capsules, 5 count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
Description
Temozolomide Capsules Description
Product name: Temozolomide capsules (Chuangnuo/Maishian)
Packing specifications: 100mg*5 capsules Product dosage form: capsules Packing unit: box
Approval number: National Medicine Standard H20234716 Drug standard code: 86900647000336
Manufacturer: Shanghai Chuangnuo Pharmaceutical Co., Ltd.
Product barcode: 6973850270180
Temozolomide (TMZ) is an oral alkylating chemotherapeutic used worldwide in brain cancer treatment, notably glioblastoma multiforme and anaplastic astrocytoma. It’s rapidly absorbed, crosses the blood–brain barrier, and converts into the active alkylating metabolite MTIC
Clinically co-administered with radiotherapy, TMZ improved median survival in glioblastoma patients from 12.1 to 14.6 months
Research applications include:
Preclinical glioblastoma models
MGMT promoter methylation studies
DNA repair / MMR pathway research
Combination therapy investigations (e.g., TMZ + olaparib)
Product Specifications
| Parameter | Details |
|---|---|
| Drug Name | Temozolomide Capsules |
| Strength & Quantity | 100mg capsules × 5 per pack |
| Dosage Form | Oral hard capsules |
| Manufacturer | Shanghai ChuanNuo Pharmaceutical Co., Ltd. |
| Approval Number (NMPA) | H20234716 |
| Pharmaceutical Code | 86900647000336 |
| Barcode | 6973850270180 |
| Storage Conditions | Store 30°C in dry place |
| Shelf Life | As labeled |
| Intended Use | For laboratory research or analysis only |
Mechanism & Research Applications
Alkylating agent: Methylates DNA bases (O6-, N7-guanine), inducing cytotoxic lesions.
MGMT / MMR dependency: DNA repair pathways strongly affect sensitivity to TMZ – critical in preclinical resistance models pubmed.ncbi.nlm.nih.gov.
Pharmacokinetics: Nearly 100% oral bioavailability, low protein binding (15–20%), half-life ~1.8h, renal excretion.
Combination research: Works synergistically with PARP inhibitors, radiosensitizers, and novel drug delivery systems.
Why Choose ChuanNuo Temozolomide?
Clinical-grade API from an NMPA-approved source
Perfect for glioblastoma and DNA repair research
Reliable capsule dosage for accurate dosing protocols
Supports oncology pipeline development and resistance studies
Lomustine, BCNU (Gliadel wafers)
PARP inhibitors: Olaparib, Niraparib
DNA methylation assay reagents
MGMT and MMR pathway modulators
Summary
ChuanNuo Temozolomide 100?mg capsules provide a high-quality, research-grade alkylating agent with clear regulatory approval, ideal for preclinical glioblastoma and DNA repair studies.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 26 × 25 × 26 cm |
1 review for Temozolomide Capsules
Related products
Mechlorethamine Hydrochloride Injection
Mechlorethamine hydrochloride (HaiPu®) is a potent DNA-alkylating agent from the nitrogen mustard class, supplied as a 1mL vial containing 5mg. Manufactured by Shanghai Xudong Haipu Pharmaceutical Co., Ltd., with NMPA approval H31020897 and product code 86900808000625. Strictly for laboratory research use.Please consult the staff for other purposes. $1.00Clodronate Disodium Capsules
Clodronate Disodium Capsules are a bisphosphonate medication used to inhibit osteoclast-mediated bone resorption. Manufactured by Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. and approved by China’s NMPA (National Medical Products Administration) under approval number H19980041. $2.00Cetuximab NO1 Injection
Cetuximab NO1 Injection, 100mg in 50mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology $1.00Lparomlimab & Tuvonralimab Injection
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination developed by Qilu Pharmaceutical (QL1706), supplied as 50mg in 2mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use. $1.00
nita –
Got it, thank you, love you